Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham,

Published byClementine Grégoire Modified over 5 years ago

Similar presentations

Presentation on theme: "Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham,"— Presentation transcript:

1 Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham, MD, William H. Yang, MD, Martin R. Pedersen, MSc-Pharm, Niels Johansen, MSc-Chem Eng, Sabina Rak, MD  Journal of Allergy and Clinical Immunology  Volume 117, Issue 4, Pages (April 2006) DOI: /j.jaci Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Trial profile. Participants received double-blind trial medication once daily (placebo, 2500, 25,000, 75,000 SQ-T grass-pollen tablets) and single-blind Step 1 rescue medication as needed (loratadine or placebo; depicted as /active or /placebo). Sixty-five participants withdrew after randomization for the following reasons: adverse events (26), physician or sponsor decision (4), consent withdrawn (5), noncompliance (5), lack of or insufficient efficacy (4), protocol deviation (3), intake of excluded medication (2), lost to follow-up (9), and other (7). ITT, Intention-to-treat analysis set, defined as all randomized participants (n = 855); PP, per-protocol analysis set, defined as randomized participants who had completed the trial and taken sufficient trial medication (at least 80%) and provided sufficient diary data (at least 30% in 50% of the weeks; n = 748); Pre, preseasonal analysis set; participants with at least 8 weeks treatment before the grass pollen season (n = 640). Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 Percentage reduction in the active treatment groups relative to the placebo group. The analyses for the entire (black bars) and peak (grey bars) pollen season included participants receiving active Step 1 medication. White bars show analysis for subjects receiving trial medication for at least 8 weeks before the grass pollen season; ∗data for 75,000 SQ-T are pooled data, entire pollen season (ie, participants receiving similar trial medication with active or placebo Step 1 rescue medication were pooled). A, Mean rhinoconjunctivitis symptom scores. B, Mean rhinoconjunctivitis medication scores. C, Induction of blocking antibodies. IgX is a measure of the level of inhibitory components to specific IgE–P pratense allergen binding and is a ratio of 2 IgE measurements. The figure shows the increase in inhibitory components relative to placebo. App., Approximately. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

4 Fig 3 Immunologic changes after treatment with placebo or grass pollen tablets 2500, 25,000, or 75,000 SQ-T. The amounts of specific (A) IgG and (B) IgE to Phleum pratense allergen are given in RU and kU/L, respectively. App, Approximately. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Download ppt "Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham,"

Similar presentations

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,

Nasal filters for the treatment of allergic rhinitis: A randomized, double-blind, placebo- controlled crossover clinical trial  Peter Kenney, BA, BSc,
Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
The Journal of Allergy and Clinical Immunology: In Practice

The Journal of Allergy and Clinical Immunology: In Practice
Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever  Laura Hatzler, Valentina Panetta,

Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever  Laura Hatzler, Valentina Panetta,
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,

Intradermal grass pollen immunotherapy increases TH2 and IgE responses and worsens respiratory allergic symptoms  Anna Slovick, MRCS, Abdel Douiri, PhD,
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Similar presentations

Ads by Google